Using the Wald chi-square for statistical analysis showed that the combination of PLX4720 and anti-PD-L1 antibody acted synergistically, and was the most effective in reducing tumor volume compared to all other treatment groups (147.3±60.8 mm3, showing a dramatic 81% tumor volume reduction compared to control (P < 0.001) and impressively over 66% better than those treated with PLX4720 alone (P=0.023) (Figure 6B, 6C). The gene discussed is CD274; the disease is neoplasm.